Top Markets
Coin of the day
Gamida Cell Ltd. Gamida Cell Ltd.

Gamida Cell Ltd.

GMDA
Ранг среди акций #35164
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated... Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Цена акции
$0.0327
Последняя синхронизация: 2025-06-17
Рыночная капитализация
$4.34M
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
IL
Торговля Gamida Cell Ltd. (GMDA)

Категория

Коэффициент P/B для Gamida Cell Ltd. (GMDA)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Gamida Cell Ltd., текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для Gamida Cell Ltd. с 2026 по 2026
Коэффициент P/B в конце каждого года
Год P/B Изменить
Недостаточно данных для указанных дат.
Коэффициент P/B для аналогичных компаний или конкурентов
Компания P/B Разница P/B Страна
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE